Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Shattuck Labs (STTK)

Shattuck Labs Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STTK
DateTimeSourceHeadlineSymbolCompany
20/02/202514:00GlobeNewswire Inc.Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025NASDAQ:STTKShattuck Labs Inc
13/02/202521:30GlobeNewswire Inc.Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025NASDAQ:STTKShattuck Labs Inc
12/02/202514:33Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STTKShattuck Labs Inc
04/02/202512:00GlobeNewswire Inc.Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis CongressNASDAQ:STTKShattuck Labs Inc
28/01/202523:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
28/01/202523:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
28/01/202523:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
28/01/202522:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
13/01/202522:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STTKShattuck Labs Inc
06/01/202521:59GlobeNewswire Inc.Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STTKShattuck Labs Inc
02/01/202512:00GlobeNewswire Inc.Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025NASDAQ:STTKShattuck Labs Inc
25/11/202412:00GlobeNewswire Inc.Shattuck Labs Announces Participation in Upcoming December ConferencesNASDAQ:STTKShattuck Labs Inc
14/11/202412:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STTKShattuck Labs Inc
14/11/202412:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
14/11/202412:00GlobeNewswire Inc.Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:STTKShattuck Labs Inc
08/11/202419:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:STTKShattuck Labs Inc
01/10/202410:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
01/10/202410:30GlobeNewswire Inc.Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling PathwayNASDAQ:STTKShattuck Labs Inc
01/08/202420:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STTKShattuck Labs Inc
01/08/202420:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
01/08/202420:05GlobeNewswire Inc.Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:STTKShattuck Labs Inc
30/07/202421:00GlobeNewswire Inc.Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology ConferenceNASDAQ:STTKShattuck Labs Inc
01/07/202410:00GlobeNewswire Inc.Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® IndexesNASDAQ:STTKShattuck Labs Inc
14/06/202410:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
14/06/202410:00GlobeNewswire Inc.Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid LeukeNASDAQ:STTKShattuck Labs Inc
11/06/202420:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:STTKShattuck Labs Inc
10/06/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STTKShattuck Labs Inc
10/06/202411:30GlobeNewswire Inc.Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)NASDAQ:STTKShattuck Labs Inc
06/06/202411:30GlobeNewswire Inc.Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk MyeNASDAQ:STTKShattuck Labs Inc
14/05/202420:15GlobeNewswire Inc.Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the EuNASDAQ:STTKShattuck Labs Inc
 Showing the most relevant articles for your search:NASDAQ:STTK